相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Thyora Therapeutics emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry to address high-unmet medical needs. - The company's foundation rests on breakthrough bicyclobutane (BCB) strain-release chemistry published in Science, demonstrating exceptional cysteine selectivity in preclinical studies. - Thyora secured exclusive worldwide rights from Moffitt Cancer Center to its BCB warhead technology and the Covalogic™ AI-enabled chemoproteomics discovery platform. - The company is initially focused on oncology, aiming to create precision covalent therapeutics against disease targets long considered undruggable.
- Frank Carter, diagnosed with mantle cell lymphoma in 2021, achieved complete remission following CAR T-cell therapy at Moffitt Cancer Center and has remained cancer-free for over four years. - After 15 rounds of chemotherapy failed to eliminate residual disease, Carter received a one-time infusion of genetically engineered autologous T cells targeting his cancer. - Carter celebrated his recovery by hand-building a cedar-strip canoe and paddling 2,341 miles down the Missouri River over 64 days with his dog, Amos. - The case highlights the durable efficacy of CAR T-cell immunotherapy in relapsed or refractory mantle cell lymphoma, a rare B-cell malignancy.
- RyboDyn received a $1.3 million award from the U.S. Department of War (DOW) through the CDMRP Peer Reviewed Cancer Research Program Impact Award to advance preclinical antibody-based therapies for lung cancer. - The funding supports antibody-drug conjugate (ADC) and T-cell engager (TCE) programs against two previously undiscovered cell-surface proteins identified directly from patient tumors using the company's AI-powered RyboCypher™ platform and CypherAtlas™ knowledgebase. - RyboDyn's top-ranked cell-surface candidate is upregulated roughly 7.5-fold in about 80% of lung squamous cell carcinoma patients assessed, contrasting with HER2, which is actionable in only 15–20% of breast cancers. - The company's dark proteome atlas now spans more than 2,000 patient samples across 12 oncology indications, containing over 6 million dark RNAs, 80,000 cryptic peptides, and roughly 10,000 cancer-specific peptides with therapeutic potential.
- IP Australia issued a Notice of Acceptance for Anixa Biosciences' breast cancer vaccine patent, the first Australian patent covering the company's vaccine platform. - The patent, exclusively licensed from Cleveland Clinic, covers immunizing against human alpha-lactalbumin, a protein aberrantly expressed in certain breast cancers. - The acceptance complements existing patents in the United States, Europe, China, Japan and South Korea, where protection runs through 2040. - The vaccine met all major primary endpoints in a completed Phase 1 trial, generating protocol-defined immune responses in more than 74% of participants.
- Anixa Biosciences' breast cancer vaccine met all primary endpoints in Phase 1, demonstrating safety and tolerability at the maximum tolerated dose. - The investigational vaccine generated protocol-defined immune responses in 74% of participants, supporting advancement to Phase 2 clinical trials. - The company has partnered with Cytovance Biologics for cGMP manufacturing of clinical materials needed for the upcoming Phase 2 study. - The vaccine targets α-lactalbumin, a lactation-associated protein that re-emerges in many forms of breast cancer, offering potential therapeutic and preventive benefits.
- BioLineRx is on track to initiate a Phase 1/2a clinical trial of GLIX1 for glioblastoma treatment by the end of March 2026, marking the first-in-human study of this novel DNA damage response inhibitor. - The company received USPTO patent allowance for GLIX1 covering 90% of all cancers where cytidine deaminase is not over-expressed, extending patent protection until 2040 with possible five-year extension. - BioLineRx reported $1.2 million in revenues for 2025 from APHEXDA royalties and maintains $20.9 million cash runway extending into the first half of 2027. - The CheMo4METPANC Phase 2b trial of motixafortide in metastatic pancreatic cancer has accelerated enrollment, with interim analysis expected in 2026.
- Multiple recent studies demonstrate that immune checkpoint inhibitors are safe and effective for HIV-positive cancer patients, with response rates and survival outcomes comparable to HIV-negative patients. - Research spanning melanoma, lung cancer, and other malignancies shows no significant differences in adverse event rates between HIV-positive and HIV-negative patients receiving checkpoint inhibitor therapy. - Evidence suggests checkpoint inhibitors may also contribute to HIV cure research, with some studies indicating potential for reducing viral reservoirs and delaying viral rebound. - Findings support treating well-controlled HIV patients similarly to the general cancer population and highlight the need for greater inclusion in clinical trials.
- University of Florida researchers discovered a gut bacteria-derived compound called Bac429 that doubled immunotherapy response rates in lung cancer mouse models, reducing tumor growth by 50%. - The breakthrough addresses a critical unmet need, as only 20% of cancer patients currently respond to immune checkpoint inhibitors, leaving 80% without treatment benefit. - The natural molecule can be synthesized into a drug for human testing and could potentially boost patient responsiveness by 50% when combined with existing immunotherapy treatments. - Researchers have established a pipeline to harvest therapeutic potential from gut microbiota and formed Bebi Therapeutics Inc. to advance clinical development of these microbial-derived molecules.
- Updated overall survival data from the FLAURA2 trial show osimertinib plus chemotherapy achieved a median OS of 47.5 months versus 37.6 months with osimertinib monotherapy, with a favorable hazard ratio of 0.77. - The MARIPOSA trial demonstrated that amivantamab plus lazertinib provided a significant OS benefit compared to osimertinib monotherapy, though interpretation is complicated by lack of crossover design. - Treatment selection remains individualized, with clinicians increasingly seeking reasons to de-escalate to single-agent osimertinib based on patient performance status, quality of life goals, and toxicity considerations. - Second-line treatment options after osimertinib progression include amivantamab plus chemotherapy from MARIPOSA-2 or continuation of osimertinib with chemotherapy based on COMPEL trial data.
- Approximately 33% of patients with HR-positive, HER2-negative breast cancer derived clinical benefit from abemaciclib monotherapy after disease progression on prior CDK4/6 inhibitor therapy in the retrospective rAMBER study. - The median duration of treatment with abemaciclib was 4.0 months following disease progression on palbociclib-based treatment, with one patient achieving partial response and seven experiencing stable disease. - Genomic analysis revealed that RB1 alterations were associated with acquired or intrinsic resistance to abemaciclib, while ESR1 alterations were found across all biopsy phenotypes. - The study represents the first evaluation of abemaciclib monotherapy effectiveness after progression on CDK4/6 inhibitors, offering new perspectives on sequential CDK4/6 therapies.
